Bayesian analysis of P2Y12 inhibitors identifies clinical uncertainties and equivalence in acute coronary syndromesTrial Shows Prasugrel May Offer Benefits Over Clopidogrel for Heart Patients

medRxiv Published September 7, 2026 Study authors: Kutcher, S.; Dendukuri, N.; Dandona, S.; Brophy, J. DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that Bayesian analysis highlights specific probabilities of efficacy and equivalence among P2Y12 inhibitors.

This meta-analysis evaluates the efficacy and safety of P2Y12 inhibitors, specifically prasugrel, clopidogrel, and ticagrelor, in patients following percutaneous coronary intervention (PCI). The study utilizes a Bayesian framework to analyze a sample of 60,619 patients to determine the probability of clinical benefit and the likelihood of equivalence between treatments.

Key findings include a 70% probability of clinical efficacy benefit for prasugrel over clopidogrel (HR 0.87; 95% CrI 0.76-1.03). For ticagrelor versus clopidogrel, the results showed 76% of the posterior probability within the region of practical equivalence (HR 0.98; 95% CrI 0.82-1.18). Regarding safety, ticagrelor showed an 86% probability of meaningful bleeding harm compared to clopidogrel (HR 1.26; 95% CrI 1.01-1.63), while prasugrel showed a 51% probability of meaningful bleeding harm (HR 1.1; 95% CrI 0.88-1.26).

The authors note that the Bayesian framework highlights clinically important uncertainties and identifies regions of equivalence among P2Y12 inhibitors that were underappreciated in previous frequentist analyses. These findings suggest that while prasugrel may offer a higher probability of efficacy over clopidogrel, the distinction between these P2Y12 inhibitors involves complex nuances in risk and equivalence. Clinical application should consider these probabilities when selecting agents for patients with acute coronary syndromes.

How this fits prior evidence

This meta-analysis addresses gaps in understanding the equivalence of P2Y12 inhibitors by using a Bayesian framework. It builds upon prior evidence showing that ticagrelor monotherapy results in lower bleeding rates than DAPT and that PCI complexity does not significantly alter the safety or efficacy of potent P2Y12 inhibitor monotherapy. This study specifically quantifies the probability of clinical benefit for prasugrel and the likelihood of bleeding harm for ticagrelor compared to clopidogrel.

Researchers analyzed data from over 60,000 patients who underwent a procedure called percutaneous coronary intervention (PCI) for acute coronary syndromes. The study compared three different medications, known as P2Y12 inhibitors: prasugrel, clopidogrel, and ticagrelor. These medications are used to prevent blood clots in patients with heart conditions.

The analysis found a 70% probability that prasugrel was more effective than clopidogrel at reducing major adverse events, such as death or stroke. When comparing ticagrelor to clopidogrel, the results were less clear, showing a 76% probability that the two drugs performed similarly. However, the study did find an 86% probability that ticagrelor was associated with more major bleeding events than clopidogrel.

Because this analysis used a specific statistical method called a Bayesian framework, it highlights certain uncertainties that previous studies might have missed. While the data suggests potential benefits for prasugrel, the results for bleeding risks and other comparisons are complex. Patients should talk to their doctors to determine which medication is safest and most effective for their specific heart health needs.

What this means for you:

Prasugrel may show better efficacy than clopidogrel, but ticagrelor showed a higher risk of bleeding events.

Common questions

Is prasugrel more effective than clopidogrel?

The study found a 70% probability that prasugrel was more effective than clopidogrel at reducing major adverse events, such as death, heart attack, or stroke, in patients who had a coronary procedure.

Are there risks of bleeding with these medications?

The study found an 86% probability of significant bleeding harm when using ticagrelor compared to clopidogrel. For prasugrel compared to clopidogrel, there was a 51% probability of bleeding harm.

How does ticagrelor compare to clopidogrel?

The analysis showed a 76% probability that ticagrelor and clopidogrel performed similarly regarding major adverse events. However, ticagrelor showed a higher likelihood of causing major bleeding events.

Study Details

Study typeMeta analysis

Sample sizen = 60,619

EvidenceLevel 1

PublishedSep 2026

View Original Abstract ↓

Background: The optimal P2Y12 inhibitor after percutaneous coronary intervention (PCI) remains debated. A recent frequentist network meta-analysis (NMA) concluded prasugrel provided optimal efficacy-safety balance. We update our previous Bayesian NMA with recent trials and contrast our findings with the frequentist NMA. Methods: We extended our 2023 systematic review by adding two trials published after our search cutoff. The primary efficacy endpoint was a composite of all-cause mortality, a recurrent non-fatal myocardial infarction, or non-fatal stroke (MACE). The primary safety endpoint was study-reported major bleeding events. Bayesian network meta-analysis with a primary binomial complementary log-log model with log(time) offset and random effects was performed. A statistical workflow with prior and posterior predictive checks, convergence diagnostics, model comparisons, sensitivity analyses and probabilities for a range of practical equivalence (ROPE: HR 0.90-1.11) are also reported. Results: 19 RCTs (n = 60,619) were identified. For MACE, prasugrel's probability of a clinical efficacy benefit (hazard ratio (HR) <0.9) was 70% compared to clopidogrel (HR 0.87, 95% credible interval (CrI )0.76-1.03) and 54% compared to ticagrelor. (HR 0.89, 95% CrI 0.73-1.12). For the ticagrelor versus clopidogrel comparison 76% of the posterior probability (HR 0.98, 95%CrI 0.82-1.18) lies in the ROPE. Ticagrelor (HR 1.26, 95%CrI 1.01-1.63) and prasugrel (HR 1.1, 95%CrI 0.88-1.26) showed 86% and 51% probabilities respectively of meaningful bleeding harm (HR > 1.1) versus clopidogrel. Conclusions: Despite 19 RCTs and approximately 60,000 patients, the Bayesian framework revealed clinically important uncertainties and identified probable regions of equivalence among the different P2Y12 inhibitors that were under appreciated with the previous frequentist publication.

Bayesian analysis of P2Y12 inhibitors identifies clinical uncertainties and equivalence in acute coronary syndromesTrial Shows Prasugrel May Offer Benefits Over Clopidogrel for Heart Patients

How this fits prior evidence

Common questions

Study Details

Dual antiplatelet therapy reduces all-cause death but not MACE or myocardial infarction in MINOCA

Dual antiplatelet therapy shows survival benefits for MINOCA patients

Clinical research that matters. Delivered to your inbox.

Bayesian analysis of P2Y12 inhibitors identifies clinical uncertainties and equivalence in acute coronary syndromesTrial Shows Prasugrel May Offer Benefits Over Clopidogrel for Heart Patients

How this fits prior evidence

Common questions

More on Coronary Artery Disease

Study Details

Dual antiplatelet therapy reduces all-cause death but not MACE or myocardial infarction in MINOCA

Dual antiplatelet therapy shows survival benefits for MINOCA patients

Clinical research that matters. Delivered to your inbox.

Related in Cardiology

From Other Specialties